Cooperation experience in a multicentre study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 2, 2013, Pages 379-385

  Pradella, Paola ^a   Azzarini, Gabriella ^b   Santarossa, Liliana ^c   Caberlotto, Livio ^d   Bardin, Cristina ^d   Poz, Alessandra ^e   D'Aurizio, Federica ^e   Giacomello, Roberta ^e  

^a UNIVERSITY OF TRIESTE   (Italy)

^b Laboratory Medicine   (Italy)

^c S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^d Radiological Department   (Italy)

^e UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

acquired coagulation disorders; antiphospholipid antibodies; haemostasis; thrombosis

Indexed keywords

LUPUS ANTICOAGULANT; PHOSPHOLIPID;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; DILUTED RUSSELL VIPER VENOM TIME; FEMALE; FUNCTIONAL LUPUS ANTICOAGULANT ASSAY; HUMAN; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SILICA CLOTTING TIME;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION TESTS; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; REFERENCE VALUES; YOUNG ADULT;

VIPERINAE;

EID: 84875412663     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0382     Document Type: Article

References (33)

1. Hughes GR. The antiphospholipid syndrome: ten years on. Lancet 1993;342:341-4.
2. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498-509.
3. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001;86:83-91.
4. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
5. Pierangeli SS, de Groot PG, Dlott J, Favaloro E, Harris EN, Lakos G, et al.'Criteria'aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus 2011;20:182-90.
6. Žigon P, Ambro ŽičA, Čučnik S, Kveder T, Rozman B, Bo ŽičB. Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies. Clin Chem Lab Med 2011;49:1011-8.
7. Wong RC, Gillis D, Adelstein S, Baumgart K, Favaloro EJ, Hendle MJ, et al. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology 2004;36:63-8.
8. Pierangeli SS, Harris EN. A protocol for determination of anticardiolipin antibodies by ELISA. Nat Protoc 2008;3: 840-8.
9. Wong RC, Favaloro EJ, Adelstein S, Baumgart K, Bird R, Brighton TA, et al. Consensus Guidelines on anti-beta 2 glycoprotein I testing and Reporting. Pathology 2008;40:58-63.
10. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2000;109:704-15.
11. Galli M. Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome. Semin Thromb Hemost 2008;34:329-34.
12. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.
13. Finazzi G. The epidemiology of the antiphospholipid syndrome: who is at risk? Curr Rheumatol Rep 2001;3:271-6.
14. Pengo V. Antiphospholipid syndrome: interpretation of laboratory data. J Thromb Haemost 2011;9:402-3.
15. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost 2012;38:322-7.
16. Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. Clin Chem 2007;53:1629-35.
17. Favaloro EJ, Wong RC. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid assays. Clin Chem Lab Med 2011;49:447-61.
18. Froom P, Barak M. Lupus anticoagulant testing: analyzing fresh samples after a single centrifugation and after a 6-8 h delay. Clin Chem Lab Med 2012;50:367-70.
19. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 1991;65:320-2.
20. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995;74:1185-90.
21. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737-40.
22. Chang SH, Tillema V, Scherr D. A "percent correction" formula for evaluation of mixing studies. Am J Clin Pathol 2002;117:62-73.
23. Devreese KM. Interpretation of normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulants. Thromb Res 2007;119:369-76.
24. Pengo V, Biasiolo A, Rampazzo P, Brocco T. DRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 1999;81:256-8.
25. Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem 2001;47:1597-606.
26. Chantarangkul V, Tripodi A, Arbini A, Mannucci PM. Silica Clotting Time (SCT) as a screening and confirmatory test for detection of the Lupus Anticoagulants. Thromb Res 1992;67:355-65.
27. Montaruli B, Vaccarino A, Foli C, Rus C, Agnes C, Saitta M, et al. Lupus anticoagulant: performance of a new, fully automated commercial screening and confirmation assay. Clin Chem 2005;51:1031-3.
28. Grypiotis P, Ruffatti A, Pengo V, Tonello M, Biasiolo A, Zamboni D, et al. Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome. J Clin Lab Anal 2006;20:15-8.
29. Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 1987;57:144-7.
30. Mameli M, Barcellona D, Vannini ML, Marongiu F. High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice. Clin Chem Lab Med 2011;49:695-8.
31. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE. On behalf of the UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol 2002;119:364-9.
32. Tincani A, Filippini M, Scarsi M, Galli M, Meroni PL. European attempts for the standardization of the antiphospholipid antibodies. Lupus 2009;18:913-9.
33. Pengo V, Biasiolo A, Gresele P, Marongiu F, Erba N, Veschi F, et al. On behalf of participating centres of Italian Federation of Thrombosis Centres (FCSA). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007;5:925-30.